Tumor organoid screenings
for biological characterizations
​and functional precision medicine

We develop strategies to test drugs in 3D tumor organoid models in a fast, reliable, high-throughput, inexpensive manner. Requiring few tumor cells, we aim to extend our methods to test combination of chemotherapies or targeted therapies directly on primary tumors from patients' biopsies or surgical samples in order to personalize treatment.
Our most current work is focused on sarcoma, ovarian cancer, neuroendocrine tumors as well as neurofibromas.

• A simple high-throughput approach identifies actionable drug responses in patient-derived tumor organoids. Phan et al, Communications Biology, 2019
• Patient-Derived Tumor Organoid Rings for Histologic Characterization and High-Throughput Screening. Nguyen et al, STAR Protocols, 2020
• High-speed live cell interferometry for screening bioprinted organoids. Tebon, Wang et al, bioRxiv, 2021
• Personalized chordoma organoids for drug discovery studies. Al Shihabi et al, Science Advances, 2022

In the press: 

• Tumor ‘organoids’ may speed cancer treatment. Science News, 17 Dec 2018
• Tumor Organoids Hold Promise for Personalizing Cancer Therapy. The Scientist, 15 Jul 2019
• Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions? Cancer Therapy Advisor. 17 Apr 2019
• ​High-Throughput Technologies: Exploring Advances and Key Applications. Technology Networks, 9 Nov 2021